Monica Verduzco-Gutierrez
@mvgutierrezmd.bsky.social
Professor & Chair of Rehab Med in SATX | Mom, runner, #LatinasInMedicine, #Physiatry, #LongCOVID
⚠️ Disparities by race, sex, insurance, and geography worsen outcomes.
Rehab is not optional—it’s essential. Let’s close the gap. #StrokeRecovery #RehabMed #Physiatry
Rehab is not optional—it’s essential. Let’s close the gap. #StrokeRecovery #RehabMed #Physiatry
October 30, 2025 at 12:20 AM
⚠️ Disparities by race, sex, insurance, and geography worsen outcomes.
Rehab is not optional—it’s essential. Let’s close the gap. #StrokeRecovery #RehabMed #Physiatry
Rehab is not optional—it’s essential. Let’s close the gap. #StrokeRecovery #RehabMed #Physiatry
Bottom line:
The NASEM definition is meant to evolve... a flexible framework for research, clinical care, and policy.
Adopt it, refine it, and let evidence guide its next iteration.
🔗 Read here: link.springer.com/article/10.1...
The NASEM definition is meant to evolve... a flexible framework for research, clinical care, and policy.
Adopt it, refine it, and let evidence guide its next iteration.
🔗 Read here: link.springer.com/article/10.1...
The 2024 NASEM Long COVID Definition as a Starting Point for Research - Journal of General Internal Medicine
Journal of General Internal Medicine -
link.springer.com
October 15, 2025 at 2:49 PM
Bottom line:
The NASEM definition is meant to evolve... a flexible framework for research, clinical care, and policy.
Adopt it, refine it, and let evidence guide its next iteration.
🔗 Read here: link.springer.com/article/10.1...
The NASEM definition is meant to evolve... a flexible framework for research, clinical care, and policy.
Adopt it, refine it, and let evidence guide its next iteration.
🔗 Read here: link.springer.com/article/10.1...
Heterogeneity is expected.
Platform trials (like RECOVER-TLC) and symptom-based thresholds can help identify subgroups without excluding patients too soon.
Platform trials (like RECOVER-TLC) and symptom-based thresholds can help identify subgroups without excluding patients too soon.
October 15, 2025 at 2:49 PM
Heterogeneity is expected.
Platform trials (like RECOVER-TLC) and symptom-based thresholds can help identify subgroups without excluding patients too soon.
Platform trials (like RECOVER-TLC) and symptom-based thresholds can help identify subgroups without excluding patients too soon.
Some have criticized the definition for being too broad.
However, early research benefits from sensitivity over specificity. It helps us explore the full spectrum of post-COVID illness before narrowing it down by biomarkers or subtypes.
However, early research benefits from sensitivity over specificity. It helps us explore the full spectrum of post-COVID illness before narrowing it down by biomarkers or subtypes.
October 15, 2025 at 2:49 PM
Some have criticized the definition for being too broad.
However, early research benefits from sensitivity over specificity. It helps us explore the full spectrum of post-COVID illness before narrowing it down by biomarkers or subtypes.
However, early research benefits from sensitivity over specificity. It helps us explore the full spectrum of post-COVID illness before narrowing it down by biomarkers or subtypes.
The 2024 @theNASEM definition of Long COVID offers a consensus-based, inclusive starting point:
“An infection-associated chronic condition occurring ≥3 months after SARS-CoV-2 infection, continuous/relapsing/progressive, affecting ≥1 organ system.”
“An infection-associated chronic condition occurring ≥3 months after SARS-CoV-2 infection, continuous/relapsing/progressive, affecting ≥1 organ system.”
October 15, 2025 at 2:49 PM
The 2024 @theNASEM definition of Long COVID offers a consensus-based, inclusive starting point:
“An infection-associated chronic condition occurring ≥3 months after SARS-CoV-2 infection, continuous/relapsing/progressive, affecting ≥1 organ system.”
“An infection-associated chronic condition occurring ≥3 months after SARS-CoV-2 infection, continuous/relapsing/progressive, affecting ≥1 organ system.”